Groupe de Recherche en Uro-Oncologie
Led by Dr. Fred Saad (MD, FRSC), founder of the Oncology Urology Clinic at the University Hospital of Montreal (CHUM) and the Molecular Oncology Laboratory in Prostate Cancer at the Montreal Cancer Institute. Also, Holder of the Raymond Garneau Chair in Prostate Cancer at the University of Montreal. Our research aims to define more effective treatments for genitourinary cancers, increase life expectancy and improve quality life for prostate, kidney and bladder cancer patients.
MD, FRSC
Director, Prostate Cancer Research, Montreal Cancer Institute, CRCHUM
Full Professor Department of Surgery, University of Montreall
Uro-oncologist, Urology Department, CHUM
MD
Hemato-oncologist, CHUM
Assistant Professor, Faculty of Medicine, University of Montreal
Investigative Researcher, Cancer
MD, FRSC
Investigative Researcher, Cancer
Our Collaborators
We have established collaborative working relationships with many clinician researchers who have contributed in terms of our knowledge base. We are always open to extending our collaborative network. The researchers below have played and integral part in the success of our group.
Dr. Daniel Juneau
MD, FRSC
Nuclear Medicine Department, CHUM
Clinical investigator,
Imaging and engineering
MD, FRSC
Doctor
Urology Department, CHUM
Clinical Associate Professor
Dept of Surgery, University of Montreal
Dr. Cynthia Ménard
MD
Chief Department of radiation oncology, CHUM
Principal scientist, Imaging and engineering
Dr. Guila Delouya
MD, FRCPC, MSc
Associate clinical professor, Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montréal
Radiation oncologistCHUM
Dr. Daniel Taussky
MD
Clinical Associate Professor, Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montréal
Dr. Dominique Trudel
MD, PhD
Genitourinary and molecular pathologist Department of pathology, CHUM
Associate Clinical Professor Department of Pathology and Cell Biology, Université de Montréal
Dr. Dr. Pierre Karakiewicz
MD
Director Cancer Prognostics and Health Outcomes Unit, CHUM
Full ProfessorDepartment of Surgery, Université de Montréal
Urologic oncologist CHUM
The objectives of the research program
1
Objective One
Improve the means of predicting the prognosis of screened cancers by combining clinical elements and molecular knowledge
2
Objective Two
Develop new therapeutic strategies based on the molecular signature of cells
3
Objective Three
Develop innovative treatments; especially for advanced cancer
4
Objective Four
Improve understanding of the mechanisms of prostate cancer progression
5
Objective Five
Train young researchers in prostate cancer
6
Objective Six
Recognition as center of excellence in prostate cancer
Research Areas
Our research focuses on accelerating advances in precision medecine and immuno-oncology in the field of Prostate, Kidney and Bladder Cancer.
Prostate Cancer
Kidney Cancer
Bladder Cancer
How we compare
Are you searching for a research protocol?
The Groupe de recherche en Uro-Oncologie (GRUO) is dedicated to improving the lives of patients with genitourinary cancer. The group conducts medical research studies involving patient volunteers, allowing for the discovery of new scientific approaches and precision medicines for Prostate, Kidney and Bladder Cancers.
